10-K: PacBio 2025 Annual Report: Strategic Shift, Asset Sale & Financials

Pacific Biosciences of California, Inc. reports a strategic shift towards HiFi sequencing, an asset sale, and a net loss of $546.4 million for fiscal year 2025, alongside a decrease in cash and investments.

Summary

• Net loss for the year ended December 31, 2025, was $546.4 million, a significant increase from $309.9 million in 2024.
• Total revenue increased by 4% to $160.0 million in 2025, up from $154.0 million in 2024.
• Consumables revenue grew by 16% to $81.9 million, driven by the expanding installed base of Revio instruments.
• Instrument revenue decreased by 18% to $53.8 million, with 61 Revio systems sold in 2025 (down from 97 in 2024), partially offset by 140 Vega systems sold following its Q4 2024 commercial launch.
• Service and other revenue increased by 36% to $24.2 million, primarily due to Revio service contracts.
• Gross profit increased by 23% to $45.8 million in 2025, mainly due to higher consumable volumes and a more favorable product mix.
• Operating loss increased to $553.9 million in 2025 from $474.3 million in 2024, primarily due to $383.1 million in restructuring-related costs.
• Restructuring-related costs included $359.3 million of accelerated amortization of developed technology from the 2021 Omniome acquisition and $15.0 million in IPR&D impairment charges.
• Cash, cash equivalents, and investments decreased by 28% to $279.5 million at December 31, 2025, from $389.9 million at December 31, 2024.
• The company completed an asset disposition to Illumina Cambridge Limited on January 30, 2026, for $50.0 million in cash, related to short-read DNA sequencing technology, with net proceeds of $48.1 million after a 4% payment to former Apton equity holders.
• The company ceased development of its high-throughput short-read sequencing platform.
• Backlog decreased to $49.2 million as of December 31, 2025, from $58.6 million as of December 31, 2024, with approximately 80% expected to convert to revenue in 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for PacBio, marked by a necessary strategic pivot and asset divestiture. While the focus on HiFi long-read sequencing and the launch of Vega are positive, the substantial net loss, significant restructuring costs, and continued negative cash flow highlight ongoing financial pressures and execution risks in a highly competitive market.

Positives

• Total revenue increased by 4% year-over-year to $160.0 million.
• Consumables revenue grew by 16% to $81.9 million, indicating increased utilization of the Revio installed base.
• Successful commercial launch of the Vega benchtop long-read sequencing system in Q4 2024, with 140 units sold in 2025.
• Service and other revenue increased significantly by 36% to $24.2 million, driven by Revio service contracts.
• Gross profit increased by 23% to $45.8 million due to higher consumable volumes and a favorable product mix.
• Successful disposition of short-read DNA sequencing assets for $50.0 million in cash, streamlining focus on HiFi long-read technology.
• Expense reduction initiatives led to a $71.1 million decrease in core operating expenses (R&D and SG&A).
• The company believes existing cash, cash equivalents, and investments are sufficient to fund operating and capital requirements for at least the next 12 months.
• Manufacturing and service facilities hold ISO 13485 and ISO 9001 certifications.
• Maintains a strong intellectual property portfolio with 450 issued U.S. patents and 318 issued foreign patents.

Negatives

• Net loss significantly increased to $546.4 million in 2025 from $309.9 million in 2024.
• Operating loss increased to $553.9 million, primarily due to $383.1 million in restructuring-related costs.
• Accelerated amortization of $359.3 million related to developed technology from the 2021 Omniome acquisition, reflecting a revised estimate that the asset will no longer generate economic benefit.
• Impairment charges of $15.0 million for in-process research and development (IPR&D) assets, following the decision to cease development of the high-throughput short-read sequencing platform.
• Cash, cash equivalents, and investments decreased by 28% ($110.4 million) year-over-year.
• Instrument revenue decreased by 18%, with Revio system sales declining from 97 units in 2024 to 61 units in 2025.
• Backlog decreased to $49.2 million from $58.6 million.
• Incurred $8.1 million in excess inventory charges and $3.9 million in estimated losses on purchase commitments due due to reduced external demand and strategic initiatives.
• The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future.
• The company expects to continue to incur substantial losses and negative cash flow from operations for the foreseeable future, and does not expect to be profitable in 2026.

Risks

• Inability to successfully market, commercialize, and sell current and future products, including Revio and Vega systems, or to transition customers from prior generation products.
• Failure to achieve profitability and sustain it consistently, with expectations of continued substantial losses and negative cash flow for the foreseeable future.
• Expense reduction initiatives, including workforce reductions, could be disruptive to operations, impair investment in product development, and make it difficult to attract or retain employees.
• Insufficient cash to make required payments under debt terms or fund long-term operations, potentially necessitating additional capital raises that could dilute existing investors.
• The disposition of short-read DNA sequencing assets may still involve retained liabilities that could materially affect the business.
• Difficulties in integrating acquired businesses, technologies, or assets, or in realizing anticipated benefits from acquisitions.
• Inability to successfully develop and timely manufacture current and future products, leading to delays, defects, quality issues, or failure to meet customer specifications.
• Rapidly changing technology in life sciences could render current products obsolete, requiring continuous and costly development of new products.
• The market for sequencing systems and consumables may be smaller than estimated, or new market opportunities may not develop as quickly as expected, limiting growth.
• Dependence on third parties for manufacturing certain products and critical components, some of which are sole-sourced, posing risks of supply disruptions and increased costs.
• Reliance on a limited number of customers for a significant portion of revenue, making the company vulnerable to fluctuations in their spending budgets, especially from academic and government institutions impacted by funding reductions.
• Products are highly complex and could have unknown defects or errors, leading to claims, diversion of resources, and increased warranty costs.
• Unpredictable and lengthy sales cycles for sequencing instruments make revenue forecasting difficult and can cause significant quarterly or annual fluctuations in operating results.
• Potential impairment of goodwill or intangible assets due to adverse changes in business or economic conditions, or lower-than-expected performance.
• Adverse effects from political and economic tensions between the United States and other countries (e.g., China, Taiwan), including tariffs, export restrictions, and supply chain disruptions.
• Failure to secure, maintain, or enforce patent or other intellectual property protection, or challenges to existing IP rights by third parties.
• Involvement in legal proceedings with third parties claiming intellectual property infringement, which can be costly and divert management attention.
• Products could become subject to government regulation as medical devices by the FDA or other agencies, increasing costs and impeding commercialization efforts.
• Ethical, legal, privacy, data protection, and social concerns surrounding the use of genetic information could reduce demand for the technology.
• Disruption of critical information technology systems or material breaches in security could harm business, customer relations, and financial condition.
• Risks associated with the use of artificial intelligence and machine learning technologies, including potential for reputational harm or liability from deficiencies, inaccuracies, or biases.
• Increased scrutiny of environmental, social, or governance (ESG) responsibilities may result in additional costs and risks, and adversely impact reputation and stakeholder relationships.
• The price of common stock has been, and may continue to be, highly volatile, and sales of substantial amounts of common stock could dilute ownership and depress the market price.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult and limit stockholders' ability to replace management.
• The company may not have the ability to raise funds necessary to settle conversions of convertible notes in cash or to repurchase them upon a fundamental change, and future debt may contain limitations on these abilities.
• The Side Letter to the 2029 Notes imposes operating restrictions, including on incurring additional indebtedness and creating liens, which could affect financing and business flexibility.

Future Outlook

The company's main objectives for 2026 are to grow revenue and expand gross margins by accelerating samples onto the Revio platform through SPRQ-Nx chemistry and application kits, expanding Vega benchtop platform capabilities, progressing its clinical strategy, advancing data-driven interpretation with HiFi datasets and AI, and investing in future product launches. It expects consumables revenue to increase due to a growing installed base and enhanced platform economics. The company believes it can be a market leader in whole-genome clinical sequencing and plans to pursue partner collaborations. However, it anticipates continued substantial losses and negative cash flow from operations for the foreseeable future and does not expect to be profitable in 2026. Approximately 80% of the current backlog is expected to convert to revenue in 2026, with significantly lower amortization expense anticipated in future periods.

Management Comments

• Our mission is to enable the promise of genomics to better human health.
• We believe that unleashing the full potential of genomics will require a level of accuracy and completeness inaccessible to legacy technologies.
• Accuracy and completeness are central to our product development strategy; thus, we have created some of the most innovative and high-quality genomics solutions on the market.
• We continue to believe that with the capabilities of our technology, we can be a market leader in whole-genome clinical sequencing.
• We plan to continue to pursue partner collaborations where the technologies being developed or applications being considered extend beyond whole-genome clinical sequencing.
• We believe that our existing cash, cash equivalents, and investments will be sufficient to fund our projected operating and capital requirements for at least the next 12 months from the date of filing of this Annual Report on Form 10-K for the year ended December 31, 2025.

Industry Context

StockSavvy.ai notes that Pacific Biosciences operates in a highly competitive and rapidly evolving life science technology market, characterized by significant technological changes and frequent new product introductions. The company's strategic shift to focus on HiFi long-read sequencing, while divesting short-read assets, positions it against established players like Illumina and emerging competitors such as Oxford Nanopore Technologies. The emphasis on accuracy, completeness, and multi-omic capabilities aligns with broader industry trends towards more comprehensive genomic insights, particularly in rare disease, oncology, and plant/animal sciences. However, the industry faces challenges from funding uncertainties in academic and government research, pricing pressures, and the need for robust third-party ecosystems for sample preparation and bioinformatics.

Comparison to Industry Standards

• HiFi whole-genome sequencing has approximately doubled the solve rate for previously undiagnosed cases compared to short-read methods in multiple clinical studies.
• HiFi sequencing supports the construction of complete, telomere-to-telomere human reference genomes and pangenomes, establishing it as a standard for high-accuracy, comprehensive genome analysis.
• The company competes with Illumina, BGI Genomics (MGI/Complete Genomics), Thermo Fisher Scientific Inc., Oxford Nanopore Technologies Ltd., Roche Holding AG, Qiagen N.V., Element Biosciences, Inc., Bionano Genomics, Inc., Ultima Genomics, Inc., and 10x Genomics, Inc., many of whom have greater resources and market recognition.

Management Changes

Corporate Governance

Legal Proceedings

• Personal Genomics of Taiwan, Inc. (PGI) filed a patent infringement complaint (C.A. No. 19-cv-1810) in the U.S. District Court for the District of Delaware against PacBio, alleging infringement by Sequel systems of U.S. Patent No. 7,767,441. A trial date is set for October 5, 2026.
• PacBio previously filed two inter-partes review (IPR) petitions against PGI's '441 Patent, with the U.S. Court of Appeals for the Federal Circuit affirming both IPR decisions on January 9, 2024.
• PGI has also filed claims against PacBio in the Wuhan People's Court in China.
• The company was previously involved in legal proceedings with Oxford Nanopore Technologies (ONT) and Harvard University in several United States and European jurisdictions for patent infringement, with ONT also filing claims against PacBio.

Related Party Transactions

• SB Northstar LP (SBN), a subsidiary of SoftBank Group Corp., is a holder of the 2029 Convertible Senior Notes and was involved in the 2024 Exchange Transaction. A Letter Agreement with SBN imposes certain negative covenants on the company, restricting its ability to incur additional indebtedness and create liens, as long as SBN and its affiliates hold at least $180 million aggregate principal amount of the 2029 Notes.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises, continued stock price volatility, and the company's policy of not paying dividends in the foreseeable future. Anti-takeover provisions may also limit their influence.
• Employees are impacted by workforce reductions as part of expense reduction initiatives, which could affect morale, productivity, and talent retention. A new Executive Incentive Compensation Plan has been adopted.
• Customers may experience delays in new capital equipment acquisitions due to funding constraints, and their adoption of products may depend on the availability of third-party sample preparation and informatics tools.
• Suppliers, particularly limited and sole-source providers, are critical to the company's operations, and any disruptions or increased costs could impact the company's ability to meet demand.
• Creditors, specifically holders of the convertible notes, have rights senior to common stockholders and are subject to the company's ability to make required payments or repurchases. The Side Letter with SBN imposes operating restrictions on the company.

Next Steps

• Accelerate samples onto the Revio platform through SPRQ-Nx chemistry and application kits.
• Expand the capabilities of the Vega benchtop platform through software improvements.
• Progress clinical strategy to improve outcomes and create durability, with Revio adoption in LDT and clinical research settings.
• Advance data-driven interpretation through scalable HiFi datasets and AI-assisted approaches, including collaborative initiatives like the HiFi Solves Global Consortium.
• Invest in future product launches to drive platform innovation, increasing throughput, simplifying workflows, lowering genome sequencing costs, and enhancing data analysis.
• Convert approximately 80% of the current backlog to revenue in 2026, and 16% in 2027.
• File definitive Proxy Statement for 2026 Annual Meeting of Stockholders within 120 days after fiscal year end.
• Full commercial availability of SPRQ-Nx chemistry planned for 2026.
• Payment to former Apton equity holders expected in Q1 2026.
• Trial date for PGI District Court matter set for October 5, 2026.
• Board of directors will be fully declassified by the 2027 Annual Meeting.

Key Dates

Recommendation

StockSavvy.ai recommends a "Hold" for PACB. While the strategic pivot to focus on HiFi long-read sequencing and the divestiture of short-read assets are positive steps towards streamlining the business, the company faces significant financial headwinds. The substantial net loss, increased operating loss due to restructuring, and continued negative cash flow indicate ongoing challenges. The decline in Revio instrument sales is concerning, though the launch of Vega and growth in consumables offer some offset. The company's ability to achieve profitability in the near future is uncertain, and potential future capital raises could dilute existing shareholders. Investors should monitor the execution of the strategic initiatives, particularly the ramp-up of Revio and Vega sales and the impact of SPRQ-Nx chemistry, as well as the company's progress towards sustainable cash flow and profitability before considering further investment. The current environment suggests a period of transition with considerable risk.

Keywords

Genomics, DNA sequencing, HiFi sequencing, SMRT technology, Revio system, Vega system, Long-read sequencing, Biotechnology, Genetic analysis, SEC filing, 10-K, Financial report, Corporate governance, Risk management, Intellectual property, Capital markets, PACB, Asset sale, Restructuring, Impairment charges, Convertible notes